Posted by Michael Wonder on 03 Jun 2017
Recommendation made by the PBAC - April 2017
2 June 2017 - PBAC publishes single outcome from out of session meeting.
The outcome (recommendation) relates to the use of vemurafenib (Zelboraf) for use by certain patients with malignant melanoma.
